Microdosing Ketamine: Where Clinical Low-Dose Use and Self-Directed Practice Diverge

What is Microdosing Ketamine

There are two genuinely different things sometimes both called “low-dose” or “microdose” ketamine. Let’s go over what they are.

Clinical subanesthetic ketamine refers to a substantial and growing body of clinical research supporting low-dose (subanesthetic) ketamine infusions, administered intravenously in supervised medical settings, for treatment-resistant depression. This is genuinely well-studied — multiple randomized, double-blind, placebo-controlled trials, including in adolescent, elderly, postpartum, and general treatment-resistant depression populations, support its short-term antidepressant effects. Typical clinical doses fall in a specific, medically administered range (commonly cited around 0.5 mg/kg by infusion).

Self-directed recreational microdosing means taking small, sub-dissociative amounts of ketamine outside a clinical setting, without medical supervision, typically via non-IV routes such as oral, sublingual, or insufflated administration. This practice is far less studied than clinical subanesthetic use. There is limited controlled research specifically on self-directed, non-clinical ketamine microdosing patterns, motivations, or safety. Reported doses for self-directed microdosing are typically 0.1-0.2 mg/kg.

There is no published research — Canadian or otherwise — on self-directed ketamine microdosing prevalence or effects within the LGBTQ community, or within any general population, as distinct from the clinical subanesthetic literature described above. This gap is worth stating plainly rather than inferring a pattern from adjacent data and unlike mushrooms or LSD where there has been more research.

Harm Reduction: Tips and Advice

For anyone engaging in self-directed use regardless, the overdose-risk information from the full-dose ketamine article still applies. Ketamine is a central nervous system depressant, and combining it with other depressants — alcohol, GHB/GBL, opioids — sharply increases risk, at any dose.

Bladder and urinary tract risk may be particularly relevant to a microdosing pattern. “Ketamine bladder” is specifically associated with regular, repeated use over time, which makes it arguably more relevant to microdosing — where the defining feature is regularity — than to occasional recreational use.

Be specific and transparent with health care providers. Given the significant overlap in terminology between clinical subanesthetic ketamine and self-directed microdosing, readers discussing ketamine use with a doctor — for any reason — should be clear about which they mean.

---

Frequently Asked Questions

---

Related Articles in This Series

• Ketamine and the LGBTQ Community
• GHB and the LGBTQ Community
• MDMA and the LGBTQ Community
• Mushrooms and the LGBTQ Community
• LSD and the LGBTQ Community

---